LCTX insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
Joint filing · 3 reporting ownersLineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Indirect ownership · See Footnote · Reported balance after transaction: 50560992 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $0.00 0 shares/units | SEC 4 | From owner profile |
Joint filing · 3 reporting ownersLineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 50560992 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $770,700.00 1,000,000 shares/units | SEC 4 | From owner profile |
| Mulroy Michael H. Director · Lineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 328555 · SEC code covers open-market or private transactions · The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8656 to $0.8755 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1. | 2026-11-17 | 2026-11-19 | ≈ $26,100.00 30,000 shares/units | SEC 4 | Follow |
| ANDREWS DEBORAH J Director · Lineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 40578 · SEC code covers open-market or private transactions | 2026-11-16 | 2026-11-17 | ≈ $20,000.00 25,000 shares/units | SEC 4 | Follow |
| Culley Brian M President and CEO · Director · Lineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 296016 · SEC code covers open-market or private transactions · 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $1.00 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1. | 2026-11-16 | 2026-11-17 | ≈ $37,098.00 40,500 shares/units | SEC 4 | Follow |
| Howe Jill Ann Chief Financial Officer · Lineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 45500 · SEC code covers open-market or private transactions · 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.84 to $0.94 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1. | 2026-11-16 | 2026-11-16 | ≈ $17,100.00 20,000 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.